Treatment of Bullous Pemphigoid with 10 or Fewer New Blisters per Day and BPDAI Below 57 (Mild–Moderate Disease)
This protocol addresses bullous pemphigoid presenting with limited blistering activity — specifically, no more than 10 new blisters per day alongside a Bullous Pemphigoid Disease Area Index (BPDAI) score below 57, covering both mild and moderate severity strata.
Clinical Scenario
Mild disease is defined by a BPDAI score below 20. Moderate disease falls between a BPDAI of 20 and below 57. Both subgroups share the hallmark of 10 or fewer new blisters daily, and may also include limited non-bullous inflammatory lesions across different body areas. Accurate BPDAI scoring guides the placement of the patient within this spectrum and informs treatment intensity.
Treatment Goal
The primary target is disease control — the point at which new lesions and pruritic symptoms cease to form and established lesions begin to heal. Evidence indicates that a substantial proportion of patients in both the mild and moderate groups can reach this endpoint within three weeks of initiating first-line therapy.
Treatment Approach (partial)
First-line management centres on corticosteroid therapy, which may be delivered topically at high potency or orally at medium dose — the two principal pathways recommended for this severity range.
Additional options and their combinations are detailed in the full protocol →
References
- It is recommended to define mild/moderate BP as the occurrence of 10 or less new blisters per day or by the presence of few non-bullous inflammatory lesions in different localizations.
- It is recommended to use the BPDAI scoring system; mild BP corresponds to a severity score lower than 20 points, and moderate BP corresponds to a BPDAI score < 57 points (4.76 ± 0.59).
- High-potency topical CS with an initial dose of clobetasol propionate of 20 to 30 g per day, applied twice or once a day (4.68 ± 0.62).
- Medium doses of oral CS, that is, oral prednisone 0.5 mg/kg/day (4.90 ± 0.36).
- Three other therapeutic options may be considered either alone or in combination with topical or oral CS.
- Doxycycline 200 mg daily (3.83 ± 1.37).
- Methotrexate, 10–12.5 mg/week initially (3.54 ± 1.55) (if no contraindication including renal insufficiency, otherwise reduce doses or avoid).
- Dapsone (1 mg to 1.5 mg/kg daily) (3.83 ± 1.30).
- According to the consensus statement, CDA is defined as the point at which new lesions or pruritic symptoms cease to form and established lesions begin to heal.
- A recent prospective observational multicentre study has indicated that a 0.5 mg/kg/day starting dose of prednisone allows disease control to be achieved at day 21 in 75% and 69% of patients with mild and moderate BP, respectively, but in only 46% of patients with severe BP.